ArticleAnnals of translational medicine2022
The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study.
Guofeng Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.